Characteristics of pericardial effusions in patients with leukemia

Keeran Sampat, Adriana Rossi, Valentin Garcia-Gutierrez, Jorge Cortes, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Little information exists regarding the prevalence and natural history of pericardial disease in patients with leukemia. Recently, it has been reported that the use of histone deacetylase inhibitors is associated with an increased incidence of pericardial effusions (PEs). To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center. METHODS: The authors reviewed 2592 patients with acute myeloid leukemia (AML, n = 1282, 49%), acute lymphocytic leukemia (ALL, n = 336, 13%), or myelodysplastic syndrome (MDS, n = 974, 38%), who were evaluated from August 2003 to July 2008. Electronic medical records were reviewed to select patients who had undergone at least 1 echocardiographic evaluation. Data regarding diagnosis, timing, effusion size, survival, and prior therapy were collected for the patients who had echocardiographic evidence of PEs. RESULTS: PEs were detected in 325 (20%) of the patients who had echocardiograms: 21% in AML, 23% in ALL, and 18% in MDS patients. Only a small portion of PEs were detected before the initiation of therapy: 26% in AML, 25% ALL, and 15% in MDS patients. Most PEs were of minimal size (70%) overall. No significant differences in effusion characteristics, including severity, were observed among different types of therapies. The presence of PEs had no impact on the survival of the patients evaluated. CONCLUSIONS: PEs are relatively common in patients with leukemia and do not appear to be related to specific types of therapy or to survival.

Original languageEnglish (US)
Pages (from-to)2366-2371
Number of pages6
JournalCancer
Volume116
Issue number10
DOIs
StatePublished - May 15 2010
Externally publishedYes

Fingerprint

Pericardial Effusion
Leukemia
Survival
Therapeutics
Histone Deacetylase Inhibitors
Electronic Health Records
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia

Keywords

  • Histone deacetylase inhibitors
  • Leukemia
  • Myelodysplastic syndrome
  • Pericardial effusions

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sampat, K., Rossi, A., Garcia-Gutierrez, V., Cortes, J., Pierce, S., Kantarjian, H., & Garcia-Manero, G. (2010). Characteristics of pericardial effusions in patients with leukemia. Cancer, 116(10), 2366-2371. https://doi.org/10.1002/cncr.24946

Characteristics of pericardial effusions in patients with leukemia. / Sampat, Keeran; Rossi, Adriana; Garcia-Gutierrez, Valentin; Cortes, Jorge; Pierce, Sherry; Kantarjian, Hagop; Garcia-Manero, Guillermo.

In: Cancer, Vol. 116, No. 10, 15.05.2010, p. 2366-2371.

Research output: Contribution to journalArticle

Sampat, K, Rossi, A, Garcia-Gutierrez, V, Cortes, J, Pierce, S, Kantarjian, H & Garcia-Manero, G 2010, 'Characteristics of pericardial effusions in patients with leukemia', Cancer, vol. 116, no. 10, pp. 2366-2371. https://doi.org/10.1002/cncr.24946
Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H et al. Characteristics of pericardial effusions in patients with leukemia. Cancer. 2010 May 15;116(10):2366-2371. https://doi.org/10.1002/cncr.24946
Sampat, Keeran ; Rossi, Adriana ; Garcia-Gutierrez, Valentin ; Cortes, Jorge ; Pierce, Sherry ; Kantarjian, Hagop ; Garcia-Manero, Guillermo. / Characteristics of pericardial effusions in patients with leukemia. In: Cancer. 2010 ; Vol. 116, No. 10. pp. 2366-2371.
@article{8b01aa8e32724cc8acb76b1a6a15a36e,
title = "Characteristics of pericardial effusions in patients with leukemia",
abstract = "BACKGROUND: Little information exists regarding the prevalence and natural history of pericardial disease in patients with leukemia. Recently, it has been reported that the use of histone deacetylase inhibitors is associated with an increased incidence of pericardial effusions (PEs). To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center. METHODS: The authors reviewed 2592 patients with acute myeloid leukemia (AML, n = 1282, 49{\%}), acute lymphocytic leukemia (ALL, n = 336, 13{\%}), or myelodysplastic syndrome (MDS, n = 974, 38{\%}), who were evaluated from August 2003 to July 2008. Electronic medical records were reviewed to select patients who had undergone at least 1 echocardiographic evaluation. Data regarding diagnosis, timing, effusion size, survival, and prior therapy were collected for the patients who had echocardiographic evidence of PEs. RESULTS: PEs were detected in 325 (20{\%}) of the patients who had echocardiograms: 21{\%} in AML, 23{\%} in ALL, and 18{\%} in MDS patients. Only a small portion of PEs were detected before the initiation of therapy: 26{\%} in AML, 25{\%} ALL, and 15{\%} in MDS patients. Most PEs were of minimal size (70{\%}) overall. No significant differences in effusion characteristics, including severity, were observed among different types of therapies. The presence of PEs had no impact on the survival of the patients evaluated. CONCLUSIONS: PEs are relatively common in patients with leukemia and do not appear to be related to specific types of therapy or to survival.",
keywords = "Histone deacetylase inhibitors, Leukemia, Myelodysplastic syndrome, Pericardial effusions",
author = "Keeran Sampat and Adriana Rossi and Valentin Garcia-Gutierrez and Jorge Cortes and Sherry Pierce and Hagop Kantarjian and Guillermo Garcia-Manero",
year = "2010",
month = "5",
day = "15",
doi = "10.1002/cncr.24946",
language = "English (US)",
volume = "116",
pages = "2366--2371",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Characteristics of pericardial effusions in patients with leukemia

AU - Sampat, Keeran

AU - Rossi, Adriana

AU - Garcia-Gutierrez, Valentin

AU - Cortes, Jorge

AU - Pierce, Sherry

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

PY - 2010/5/15

Y1 - 2010/5/15

N2 - BACKGROUND: Little information exists regarding the prevalence and natural history of pericardial disease in patients with leukemia. Recently, it has been reported that the use of histone deacetylase inhibitors is associated with an increased incidence of pericardial effusions (PEs). To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center. METHODS: The authors reviewed 2592 patients with acute myeloid leukemia (AML, n = 1282, 49%), acute lymphocytic leukemia (ALL, n = 336, 13%), or myelodysplastic syndrome (MDS, n = 974, 38%), who were evaluated from August 2003 to July 2008. Electronic medical records were reviewed to select patients who had undergone at least 1 echocardiographic evaluation. Data regarding diagnosis, timing, effusion size, survival, and prior therapy were collected for the patients who had echocardiographic evidence of PEs. RESULTS: PEs were detected in 325 (20%) of the patients who had echocardiograms: 21% in AML, 23% in ALL, and 18% in MDS patients. Only a small portion of PEs were detected before the initiation of therapy: 26% in AML, 25% ALL, and 15% in MDS patients. Most PEs were of minimal size (70%) overall. No significant differences in effusion characteristics, including severity, were observed among different types of therapies. The presence of PEs had no impact on the survival of the patients evaluated. CONCLUSIONS: PEs are relatively common in patients with leukemia and do not appear to be related to specific types of therapy or to survival.

AB - BACKGROUND: Little information exists regarding the prevalence and natural history of pericardial disease in patients with leukemia. Recently, it has been reported that the use of histone deacetylase inhibitors is associated with an increased incidence of pericardial effusions (PEs). To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center. METHODS: The authors reviewed 2592 patients with acute myeloid leukemia (AML, n = 1282, 49%), acute lymphocytic leukemia (ALL, n = 336, 13%), or myelodysplastic syndrome (MDS, n = 974, 38%), who were evaluated from August 2003 to July 2008. Electronic medical records were reviewed to select patients who had undergone at least 1 echocardiographic evaluation. Data regarding diagnosis, timing, effusion size, survival, and prior therapy were collected for the patients who had echocardiographic evidence of PEs. RESULTS: PEs were detected in 325 (20%) of the patients who had echocardiograms: 21% in AML, 23% in ALL, and 18% in MDS patients. Only a small portion of PEs were detected before the initiation of therapy: 26% in AML, 25% ALL, and 15% in MDS patients. Most PEs were of minimal size (70%) overall. No significant differences in effusion characteristics, including severity, were observed among different types of therapies. The presence of PEs had no impact on the survival of the patients evaluated. CONCLUSIONS: PEs are relatively common in patients with leukemia and do not appear to be related to specific types of therapy or to survival.

KW - Histone deacetylase inhibitors

KW - Leukemia

KW - Myelodysplastic syndrome

KW - Pericardial effusions

UR - http://www.scopus.com/inward/record.url?scp=77952560069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952560069&partnerID=8YFLogxK

U2 - 10.1002/cncr.24946

DO - 10.1002/cncr.24946

M3 - Article

C2 - 20209609

AN - SCOPUS:77952560069

VL - 116

SP - 2366

EP - 2371

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -